Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is currently in clinical development programs for CRSwNP (phase 3), non-cystic fibrosis ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evaluating itepekimab in ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced mixed data from a Phase 3 program for itepekimab, an antibody therapy ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former smokers who have inadequately controlled chronic obstructive ...

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

While the drug, called itepekimab, met its goal in the other trial, the split findings cloud the prospects for Regeneron and Sanofi to seek approval on the basis of the current data. Instead, they ...